Pharmacyte Biotech Inc. has raised $90 million to move its live cell encapsulation technology for cancer and diabetes further into the clinic. CEO Kenneth Waggoner told BioWorld that the first task is to work through studies and gather other information required by the FDA to get a clinical hold, imposed last November, lifted on trials in pancreatic cancer.